Loading
NASDAQHealthcareBiotechnology
Latest quote
$21.98
−$0.73 · -3.21%
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Regular session
$21.98
−$0.73 · -3.21%
Regular session · ET · Market data may be delayed.
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Day range
Current $21.98
52-week range
Current $21.98
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
39
Expensive
Sentiment
61
Bullish
Risk
44
Elevated Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Day range
Current $21.98
52-week range
Current $21.98
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 63.49M USD | 41.36M USD | 36.97M USD | 25.65M USD | 10.98M USD |
| Selling, general, and administrative | 20.55M USD | 16.65M USD | 7.68M USD | 7.18M USD | 4.63M USD |
| Operating expenses | 84.04M USD | 58.02M USD | 44.65M USD | 32.83M USD | 15.61M USD |
| Interest income | 11.3M USD | 4.26M USD | 581K USD | 149K USD | — |
| Interest expense | 63K USD | 107K USD | 152K USD | 144K USD | 224K USD |
| Depreciation and amortization | 1.38M USD | 1.65M USD | 1.48M USD | 1.01M USD | 364K USD |
| Operating income | −84.04M USD | −58.02M USD | −44.65M USD | −32.83M USD | −15.61M USD |
| Net income | −74.15M USD | −57.98M USD | −42.82M USD | −32.18M USD | −8.93M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$78.67
257.92% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 21, 2024 | 1:12 | — | — |
Effective Jun 21, 2024
1:12
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM6.23M0.01%78.56B USD0.19%$275-0.97%
Vanguard Russell 2000 ETFVTWO1.77M0.01%18B USD0.06%$111.08-1.01%
iShares Biotechnology ETFIBB1.62M0.02%10.4B USD0.44%$197.71-2.77%
iShares Micro-Cap ETFIWC771.73K0.06%1.33B USD0.60%$180.97-1.30%
Vanguard Health Care ETFVHT770.75K0.00%22B USD0.09%$309.61-1.81%
ALPS Medical Breakthroughs ETFSBIO563.48K0.30%188.26M USD0.50%$52.985-2.12%
Avantis U.S. Small Cap Equity ETFAVSC491.59K0.02%3.08B USD0.25%$69.29-0.49%
iShares Russell 2000 Growth ETFIWO447.7K0.00%14.25B USD0.24%$350.71-1.31%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTALPS Medical Breakthroughs ETFSBIOAvantis U.S. Small Cap Equity ETFAVSCiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
